Novo Nordisk cuts 13,000 jobs in 12 months amid weight-loss drug competition

Novo Nordisk has reduced its workforce by 13,000 over the past year as part of cost-cutting measures, reflecting intensified competition in the weight-loss drug market. The scale of job cuts signals significant operational restructuring, though the financial impact and strategic details remain undisclosed. This development underscores margin pressure on a major pharma player, with potential implications for sector valuations.